Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
Financial Performance and Strategy news
6 November 2025
Veolia: Q3 2025 Financial Highlights
Strong Q3 2025 results: 3.2% revenue growth, 5.4% EBITDA rise, €2.3bn investments, and controlled debt. Confident in meeting annual objectives.
6 November 2025
ENGIE 9M 2025 Financial Results
Strong earnings and cash flow; FY 2025 guidance at upper range. Growth in renewables, PPAs, and flexible assets. EBIT down 7.3% due to lower energy prices. Solid balance sheet maintained.
6 November 2025
Uniper on Track for 2025 Earnings Forecast
Uniper's nine-month earnings align with expectations, despite lower figures. Cash position strong, carbon emissions reduced, and EU remedy progress made. 2025 forecast reaffirmed.
6 November 2025
Lanxess Faces Challenging Q3 2025 Market Conditions
Revenue and EBITDA decline due to weak demand and geopolitical issues. Cost reductions planned. Net debt stable. Full-year EBITDA guidance at lower range.
6 November 2025
Heidelberg Materials Reports Q3 Growth, Confirms 2025 Outlook
Q3 results up 5%, operating margin at 25.9%. Transformation Accelerator boosts savings. CCS projects advance, with evoZero cement deliveries starting. 2025 outlook remains positive.
5 November 2025
Novo Nordisk Reports 12% Sales Growth in DKK, 15% at CER, and R&D Advances in First Nine Months of 2025
Operating profit rose 5% in DKK, 10% at CER. Obesity care sales up 37%. FDA approved Wegovy® for MASH. Novo Nordisk to acquire Akero Therapeutics. Full-year sales growth forecast at 8-11% CER.
News type
New Projects and Expansions
New Projects and Expansions
Project Updates and Milestones
Project Updates and Milestones
Mergers, Acquisitions, and Partnerships
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Innovation and Product Development
Operational Changes and Investments
Operational Changes and Investments
Sustainability and Environmental Initiatives
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Financial Performance and Strategy
Executive Appointments and Governance Changes
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Analytics
Learn more
5 November 2025
Novo Nordisk Reports 12% Sales Growth in DKK, 15% at CER, and R&D Progress in First Nine Months of 2025
Operating profit rose 5% in DKK, 10% at CER. US sales up 12% in DKK, 15% at CER. R&D advances with acquisitions and new approvals. Full-year growth outlook narrowed.
4 November 2025
Merck Partners with Blackstone for Sac-TMT Development Funding
Merck receives $700M from Blackstone for sac-TMT development, retaining control over its progress and commercialization.
4 November 2025
Evonik's Q3 2025 Performance Decline
Q3 2025 saw a 22% EBITDA drop due to weak demand and lower sales. Revenue fell 12%. Efficiency programs are on track, but demand is expected to stay weak through year-end.
4 November 2025
BP Q3 2025 Financial Results
Q3 saw $7.8bn cash flow, $2.2bn RC profit. Upstream reliability at 96.8%, refining at 96.6%. $4bn+ divestments expected, $14.5bn capex on track. Net debt stable at $26.1bn.
4 November 2025
Aramco Q3 2025 Financial Results
Adjusted net income rose to $28B. Cash flow and free cash flow increased. Gearing ratio improved. Dividends declared. Investments in HUMAIN and Fujian reflect strategic growth.
3 November 2025
Ørsted Divests 50% of Hornsea 3 to Apollo
Ørsted sells 50% of Hornsea 3 to Apollo, enhancing capital structure. The deal, worth approx. DKK 39 billion, is set to close by year-end, pending regulatory approval.
3 November 2025
Eastman Q3 2025 Financial Results
Strong cash flow, inventory reduction, cost-cutting, and shareholder returns amid weak demand. Focus on cash, cost, and circular economy for future growth.
3 November 2025
Evonik Sells Betaines Business in Indonesia
Evonik divests its Bekasi site to focus on sustainable specialties, continuing its strategic shift from global betaine operations.
3 November 2025
SABIC Reports 45% Rise in Q3 2025 Net Income
Q3 revenues hit SAR 34.3B; free cash flow up 81%. MTBE project launched early. 90+ new products introduced. Local content increased by 17%.
3 November 2025
bp Sells Non-Controlling US Midstream Interests for $1.5 Billion
bp retains control of strategic assets, advancing its $20B divestment goal by 2027. Transaction involves phased payments and regulatory approvals.
31 October 2025
LyondellBasell Q3 2025 Earnings Report
Reported net loss of $890M, EBITDA of $(480)M. Cash from operations at $983M. Continued focus on operational improvements, asset sales, and cash management.
31 October 2025
Linde Q3 2025 Financial Results
Linde reports Q3 2025 results, highlighting its role in industrial gases and engineering across diverse markets, supporting sustainability and energy transition efforts.
31 October 2025
KMG Eurobonds Begin Trading on AIX
KMG debuts in the yuan market with Dim Sum bonds on AIX, diversifying funding and expanding its investor base. The issuance attracted high investor interest and positive analyst reviews.
31 October 2025
Kulzer, a Mitsui Chemicals Subsidiary, Targets EMEA and Americas
Kulzer restructures to enhance efficiency, consolidates production in Germany, and leverages digital transformation to boost sales and competitiveness in priority markets.
31 October 2025
Fuchs SE: Q3 Earnings Stable
Sales rose 1% to EUR 2,700 million in nine months. EBIT fell 2% due to market challenges. Q3 earnings improved over Q2 and last year's peak. Outlook from July confirmed.
30 October 2025
Lilly Q3 2025 Financials: Revenue Up 54%, R&D Progress, Guidance Raised
Revenue growth driven by incretin demand. Advanced orforglipron trials, FDA approval for Inluriyo. Expanded manufacturing in Virginia, Texas, Puerto Rico.
30 October 2025
Aptar Q3 2025 Financial Results
Sales up 6%, net income up 28%, EPS up 30%. Strong growth in Pharma and Closures. $70M returned to shareholders.
30 October 2025
Repsol Reports €1.177 Billion Net Income Through September
Adjusted income reached €2.173B, driven by improved Q3 results. Despite lower crude prices, net income doubled in Q3. Dividend to exceed €1/share by 2026.
30 October 2025
Merck Announces Q3 2025 Financial Results
Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.
30 October 2025
dsm-firmenich Q3 2025 Update
Solid growth in Q3 with 2% organic sales increase. Updated 2025 outlook: €2.3B Adjusted EBITDA. ANH exit ongoing. Share buyback 85% complete.
30 October 2025
Statkraft Sells Assets for NOK 13.5 Billion in Q3 2025
Statkraft's Q3 results fell due to low prices and negative hedging. Asset sales aim to reduce complexity and fund growth in prioritized markets and technologies.
30 October 2025
Technip Energies 9M 2025 Results
Revenue and EBITDA up 9% Y/Y. Acquired Ecovyst's AM&C business. Major LNG contract in the US. Strong outlook in LNG, decarbonization, and sustainable fuels.
30 October 2025
WACKER Q3 Results Align with Expectations, Adjusts Full-Year Forecast
Q3 sales fell 6% to €1.34B, EBITDA dropped 23% to €112M. Net result was €-82M. Focus on cash and costs. Full-year EBITDA in lower expected range.
30 October 2025
Covestro Q3 2025: Results Meet Expectations, Effective Cost-Cutting
Despite challenges, cost-cutting and strategic investments drive progress. Full-year forecast narrowed; focus on sustainable growth and innovation continues.
Next →
